Research Article| Volume 68, ISSUE 4, P663-671, April 2018

Download started.


Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C

Published:November 10, 2017DOI:


      • Large real-world cohort of therapy in patients infected with HCV genotype 1.
      • Eight-week treatment with ledipasvir/sofosbuvir resulted in similar SVR rates to 12 weeks treatment.
      • Very high SVR rates were achieved, so shorter treatment can be recommended.

      Background & Aims

      Ledipasvir/sofosbuvir (LDV/SOF) for 8 to 24 weeks is approved for the treatment of chronic hepatitis C virus infection (HCV). In the ION-3 study, 8 weeks of LDV/SOF was non-inferior to 12 weeks in previously untreated genotype 1 (GT1) patients without cirrhosis. According to the Summary of Product Characteristics (SmPC), 8-week treatment may be considered in naïve non-cirrhotic GT1-patients. However, there are only limited data on the effectiveness of an 8-week regimen of LDV/SOF under real-world conditions. The aim of the present study was to characterise patients receiving 8 weeks of LDV/SOF compared to those receiving 12 weeks of LDV/SOF, and to describe therapeutic outcomes in routine clinical practice.


      The German Hepatitis C-Registry is a large national real-world cohort that analyses effectiveness and safety of antiviral therapies in chronic HCV. This data set is based on 2,404 patients. Treatment with SOF/LDV (without RBV) for 8 or 12 weeks was initiated on or before September 30, 2015.


      Overall, 84.6% (2,034/2,404) of the safety population (intention-to-treat-1 [ITT1]) and 98.2% (2,029/2,066) of the per protocol (PP) population achieved sustained virological response at week 12 (SVR12). In the 8-week group, 85.1% (824/968) of ITT1 and 98.3% (821/835) of PP patients achieved SVR12, while in the 12-week group, 85.5% (1,210/1,415) of ITT1, and 98.1% (1,208/1,231) of PP patients achieved SVR12. When treated according to the SmPC, 98.7% (739/749) of the patients achieved SVR12 (PP). Relapse was observed in 9.5% (2/21) of cirrhotic patients treated for 8 weeks (PP).


      Under real-world conditions a high proportion of eligible patients receiving 8-week LDV/SOF treatment achieved SVR12. Relapse occurred more frequently in patients who did not meet the selection criteria according to the SmPC.

      Lay summary

      In a large real-world cohort of patients mainly treated by physicians in private practice in Germany, shorter HCV treatment (8-week) resulted in equivalent cure rates to 12-week treatment in genotype 1 HCV-infected patients. Thus, shorter treatment can be recommended in these patients which would substantially reduce costs of therapy.
      Clinical Trial number: DRKS00009717 (German Clinical Trials Register, DRKS)

      Graphical abstract


      Linked Article

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Hepatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Afdhal N.
        • Zeuzem S.
        • Kwo P.
        • Chojkier M.
        • Gitlin N.
        • Puoti M.
        • et al.
        Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
        N Engl J Med. 2014; 370: 1889-1898
        • Afdhal N.
        • Reddy K.R.
        • Nelson D.R.
        • Lawitz E.
        • Gordon S.C.
        • Schiff E.
        • et al.
        Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.
        N Engl J Med. 2014; 370: 1483-1493
        • Kowdley K.V.
        • Gordon S.C.
        • Reddy K.R.
        • Rossaro L.
        • Bernstein D.E.
        • Lawitz E.
        • et al.
        Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.
        N Engl J Med. 2014; 370: 1879-1888
        • European Association for Study of Liver
        EASL recommendations on treatment of hepatitis C 2015.
        J Hepatol. 2015; 63: 199-236
        • O'Brien T.R.
        • Feld J.J.
        • Kottilil S.
        • Pfeiffer R.M.
        No scientific basis to restrict 8 weeks of treatment with ledipasvir/sofosbuvir to patients with hepatitis C virus RNA <6,000,000 IU/mL.
        Hepatology. 2016; 63: 28-30
      1. Curry MP, Bacon B, Dieterich D, Flamm SL, Guest L, Kowdley KV, et al. Effectiveness of 8 or 12 week LDV-SOF in Treatment-Naïve Patients with Non-Cirrhotic, Genotype 1 Hepatitis C: Real-World Experience from the TRIO Network. Poster presented at the 66th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, Nov 13–17 2015.

        • Ioannou G.N.
        • Beste L.A.
        • Chang M.F.
        • Green P.K.
        • Lowey E.
        • Tsui J.I.
        • et al.
        Effectiveness of sofosbuvir, ledipasvir/sofosbuvir, or paritaprevir/ritonavir/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the veterans affairs national healthcare system.
        Gastroenterology. 2016; 151: 457-471
        • Terrault N.A.
        • Zeuzem S.
        • Di Bisceglie A.M.
        • Lim J.K.
        • Pockros P.J.
        • Frazier L.M.
        • et al.
        Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis C virus infection and factors associated of sustained virologic response.
        Gastroenterology. 2016; 151: 1131-1140
        • Ingiliz P.
        • Christensen S.
        • Kimhofer T.
        • Hueppe D.
        • Lutz T.
        • Schewe K.
        • et al.
        Sofosbuvir and Ledipasvir for 8 weeks for the treatment of chronic hepatitis C virus infection in HCV-mono-infected and HIV-HCV co-infected individuals- Results from the German hepatitis c cohort (GECCO-01).
        Clin Infect Dis. 2016; 63: 1320-1324
        • Backus L.I.
        • Belperio P.S.
        • Shahoumian T.A.
        • Loomis T.P.
        • Mole L.A.
        Comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in 6961 genotype 1 patients treated in routine medical practice.
        Aliment Pharmacol Ther. 2016; 44: 400-410
        • Backus L.I.
        • Belperio P.S.
        • Shahoumian T.A.
        • Loomis T.P.
        • Mole L.A.
        Real world effectiveness of ledipasvir/sofosbuvir in 4365 treatment-naïve genotype 1 hepatitis C infected patients.
        Hepatology. 2016; 64: 405-416
        • Wilder J.M.
        • Jeffers L.J.
        • Ravendhran N.
        • Shiffman M.L.
        • Poulos J.
        • Sulkowski M.S.
        • et al.
        Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data.
        Hepatology. 2016; 63: 437-444
        • Welzel T.M.
        • Zeuzem S.
        • Dumas E.O.
        • Asselah T.
        • Shaw D.
        • Hazzan R.
        • et al.
        Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial.
        Lancet Gastroenterol Hepatol. 2017; 2: 494-500
      2. Petersen J, Wursthorn K, Olah K, Lorenzen T, Plettenberg A, Unger S et al. Strong decrease of patients with advanced liver disease and more adherence problems to HCV therapy as DAA regimen enter third year of existence in Germany. Poster FRI-252 presented at The International Liver Congress 2017 of the European Association for the Study of the Liver. 2016 Apr 19–23; Barcelona, Spain.

        • Naggie S.
        • Cooper C.
        • Saag M.
        • Workowski K.
        • Ruane P.
        • Towner W.
        • et al.
        Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.
        N Engl J Med. 2015; 373: 705-713
        • Cloherty G.
        • Cohen D.
        • Sarrazin C.
        • Wedemeyer H.
        • Chevaliez S.
        • Herman C.
        HCV RNA assay sensitivity impacts the management of patients treated with direct acting antivirals.
        Antivir Ther. 2015; 20: 177-183
        • Tapper E.B.
        • Bacon B.R.
        • Curry M.P.
        • Dieterich D.T.
        • Flamm S.L.
        • Guest L.E.
        • et al.
        Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study.
        Hepatology. 2016; 64: 1893-1899